News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
Formycon AG announces positive CHMP opinion from EMA for Aflibercept-Biosimilar FYB203 (AHZANTIVE®/ Baiama®) as a treatment for retinal diseases. Market approval expected by January 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
Formycon extends CEO contract until 2027. Receives admission to trading in Frankfurt Stock Exchange's Prime Standard. Company's biosimilars contribute to healthcare accessibility and cost reduction -
-
-
-
-